Long Shot : : Vaccines for National Defense / / Kendall Hoyt.

At the turn of the twenty-first century, the United States contended with a state-run biological warfare program, bioterrorism, and a pandemic. Together, these threats spurred large-scale government demand for new vaccines, but few have materialized. A new anthrax vaccine has been a priority since t...

Full description

Saved in:
Bibliographic Details
Superior document:Title is part of eBook package: De Gruyter E-BOOK GESAMTPAKET / COMPLETE PACKAGE 2012
VerfasserIn:
Place / Publishing House:Cambridge, MA : : Harvard University Press, , [2012]
©2011
Year of Publication:2012
Language:English
Online Access:
Physical Description:1 online resource (314 p.) :; 1 halftone, 6 line illustrations, 8 tables
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 05110nam a22008055i 4500
001 9780674063150
003 DE-B1597
005 20210830012106.0
006 m|||||o||d||||||||
007 cr || ||||||||
008 210830t20122011mau fo d z eng d
019 |a (OCoLC)979739984 
019 |a (OCoLC)984686848 
019 |a (OCoLC)987949090 
019 |a (OCoLC)992472079 
019 |a (OCoLC)999381777 
020 |a 9780674063150 
024 7 |a 10.4159/harvard.9780674063150  |2 doi 
035 |a (DE-B1597)178122 
035 |a (OCoLC)773265344 
040 |a DE-B1597  |b eng  |c DE-B1597  |e rda 
041 0 |a eng 
044 |a mau  |c US-MA 
072 7 |a MED036000  |2 bisacsh 
082 0 4 |a 614.4/7  |2 23 
100 1 |a Hoyt, Kendall,   |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
245 1 0 |a Long Shot :  |b Vaccines for National Defense /  |c Kendall Hoyt. 
264 1 |a Cambridge, MA :   |b Harvard University Press,   |c [2012] 
264 4 |c ©2011 
300 |a 1 online resource (314 p.) :  |b 1 halftone, 6 line illustrations, 8 tables 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
505 0 0 |t Frontmatter --   |t Contents --   |t Text Acronyms --   |t Introduction --   |t 1. Disease, Security, and Vaccines --   |t 2. Historical Patterns of Vaccine Innovation --   |t 3. Vaccine Development during World War II --   |t 4. Wartime Legacies --   |t 5. The End of an Era --   |t 6. Biodefense in the Twenty-First Century --   |t 7. The Search for Sustainable Solutions --   |t Appendices --   |t Notes --   |t Acknowledgments --   |t Index 
506 0 |a restricted access  |u http://purl.org/coar/access_right/c_16ec  |f online access with authorization  |2 star 
520 |a At the turn of the twenty-first century, the United States contended with a state-run biological warfare program, bioterrorism, and a pandemic. Together, these threats spurred large-scale government demand for new vaccines, but few have materialized. A new anthrax vaccine has been a priority since the first Gulf War, but twenty years and a billion dollars later, the United States still does not have one. This failure is startling.Historically, the United States has excelled at responding to national health emergencies. World War II era programs developed ten new or improved vaccines, often in time to meet the objectives of particular military missions. Probing the history of vaccine development for factors that foster timely innovation, Kendall Hoyt discovered that vaccine innovation has been falling, not rising, since World War II. This finding is at odds with prevailing theories of market-based innovation and suggests that a collection of nonmarket factors drove mid-century innovation. Ironically, many late-twentieth-century developments that have been celebrated as a boon for innovation-the birth of a biotechnology industry and the rise of specialization and outsourcing-undercut the collaborative networks and research practices that drove successful vaccine projects in the past.Hoyt's timely investigation teaches important lessons for our efforts to rebuild twenty-first-century biodefense capabilities, especially when the financial payback for a particular vaccine is low, but the social returns are high. 
530 |a Issued also in print. 
538 |a Mode of access: Internet via World Wide Web. 
546 |a In English. 
588 0 |a Description based on online resource; title from PDF title page (publisher's Web site, viewed 30. Aug 2021) 
650 7 |a MEDICAL / Health Policy.  |2 bisacsh 
773 0 8 |i Title is part of eBook package:  |d De Gruyter  |t E-BOOK GESAMTPAKET / COMPLETE PACKAGE 2012  |z 9783110288995  |o ZDB-23-DGG 
773 0 8 |i Title is part of eBook package:  |d De Gruyter  |t E-BOOK PACKAGE MEDICINE 2012  |z 9783110293807  |o ZDB-23-DME 
773 0 8 |i Title is part of eBook package:  |d De Gruyter  |t E-BOOK PAKET MEDIZIN 2012  |z 9783110293791  |o ZDB-23-DMD 
773 0 8 |i Title is part of eBook package:  |d De Gruyter  |t HUP eBook-Package Backlist 2000-2013 (Canada)  |z 9783110756067 
773 0 8 |i Title is part of eBook package:  |d De Gruyter  |t Harvard University Press eBook Package Backlist 2000-2013  |z 9783110442205 
776 0 |c print  |z 9780674061583 
856 4 0 |u https://doi.org/10.4159/harvard.9780674063150 
856 4 0 |u https://www.degruyter.com/isbn/9780674063150 
856 4 2 |3 Cover  |u https://www.degruyter.com/cover/covers/9780674063150.jpg 
912 |a 978-3-11-044220-5 Harvard University Press eBook Package Backlist 2000-2013  |c 2000  |d 2013 
912 |a 978-3-11-075606-7 HUP eBook-Package Backlist 2000-2013 (Canada)  |b 2013 
912 |a EBA_BACKALL 
912 |a EBA_CL_MDPM 
912 |a EBA_EBACKALL 
912 |a EBA_EBKALL 
912 |a EBA_ECL_MDPM 
912 |a EBA_EEBKALL 
912 |a EBA_ESTMALL 
912 |a EBA_PPALL 
912 |a EBA_STMALL 
912 |a GBV-deGruyter-alles 
912 |a PDA12STME 
912 |a PDA13ENGE 
912 |a PDA18STMEE 
912 |a PDA5EBK 
912 |a ZDB-23-DGG  |b 2012 
912 |a ZDB-23-DMD  |b 2012 
912 |a ZDB-23-DME  |b 2012